Ilyang Pharmaceutical’s ‘Supect’ effectively inhibits Parkinson’s disease progress
The preclinical and efficacy result on the Ilyang Pharmaceutical’s(President Dong-Yeon Kim) chronic myelocytic leukemia treatment ‘Supect(generic name: radotinib)’ for Parkinson’s disease(PD) was announced at the ‘American Academy of Neurology(AAM)’ symposium in Washington, D.C. on the 13th of No...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
